| Parameter |
PFS |
OS |
| HR |
95% CI |
P-value |
HR |
95% CI |
P-value |
| Age>60 |
0.57 |
0.176-1.849 |
0.35 |
1.133 |
0.372-3.455 |
0.826 |
| Sex: male vs. female |
0.8 |
0.469-1.365 |
0.413 |
1.22 |
0.688-2.164 |
0.496 |
| PS ≥ 1 |
1.352 |
0.439-4.162 |
0.599 |
3.872 |
1.164-12.877 |
0.027 |
| Presence of primary site |
3.756 |
0.721-19.559 |
0.116 |
1.817 |
0.21-15.706 |
0.587 |
| Advanced vsrecurrence |
0.803 |
0.47-1.371 |
0.421 |
1.008 |
0.605-1.678 |
0.977 |
| Liver metastasis |
0.477 |
0.133-1.71 |
0.256 |
0.946 |
0.325-2.756 |
0.919 |
| Lung metastasis |
1.641 |
0.504-5.338 |
0.411 |
0.395 |
0.128-1.216 |
0.105 |
| Lymph node metastasis |
2.231 |
0.72-6.914 |
0.164 |
0.944 |
0.337-2.642 |
0.913 |
| Peritoneal metastasis |
0.927 |
0.282-3.046 |
0.9 |
2.243 |
0.721-6.978 |
0.163 |
| CEA>10 ng/ml |
1.02 |
0.22-4.726 |
0.979 |
3.031 |
0.377-24.346 |
0.297 |
| CA19-9>100 U/ml |
1.287 |
0.429-3.864 |
0.653 |
1.778 |
0.556-5.69 |
0.332 |
| Interval between Cmab and Pmab<120 days |
0.011 |
0-2.052 |
0.091 |
0.407 |
0.129-1.287 |
0.126 |
| CTC ≥ 1 |
3.277 |
0.964-11.144 |
0.057 |
2.467 |
0.81-7.51 |
0.112 |
| CTC ≥ 2 |
5.017 |
1.366-18.427 |
0.015 |
2.097 |
0.724-6.075 |
0.173 |
| CTC ≥ 3 |
3.268 |
0.913-11.698 |
0.069 |
2.091 |
0.714-6.122 |
0.178 |
HR=Hazard Ratio; CI=Confidence Interval; PS=Performance Status;
CEA=CarcinoEmbryonic Antigen; CA19-9=Carbohydrate Antigen 19-9;
Cmab=cetuximab; Pmab=Panitumumab; CTC=Circulating Tumor Cells;
PFS=Progression-Free Survival; OS=Overall Survival.
|
